TRACON Pharmaceuticals to Present at the Rodman & Renshaw 9th Annual Healthcare Conference
November 2 , 2007
San Diego, CA – November 2, 2007 – TRACON Pharmaceuticals, Inc. (TRACON), a biopharmaceutical company focused on the development of products for oncology and ophthalmology treatment, today announced that the company will be presenting at the Rodman & Renshaw 9th Annual Healthcare Conference on Wednesday, November 7, 2007, at 1:00pm EST at the New York Palace Hotel in New York City.
At the conference, President and Chief Executive Officer Charles Theuer, MD, PhD, will provide a company overview and update on the status of TRACON’s current clinical development programs. TRACON remains on track to initiate clinical trials on its third drug candidate this year. Dr. Theuer will also be available for one-on-one meetings during this conference.
“We are looking forward to the opportunity to discuss our therapeutic pipeline with those in attendance,” said Dr. Charles Theuer, President and Chief Executive Officer of TRACON Pharmaceuticals.
About TRACON Pharmaceuticals
TRACON Pharmaceuticals (www.traconpharma.com) is a privately held biopharmaceutical company focused on the development of products for oncology and ophthalmology treatment, including agents that inhibit angiogenesis. TRACON addresses unmet needs in these areas with first-in-class product candidates that will complement existing therapies. TRC093 is a monoclonal antibody that binds to cleaved collagen to inhibit angiogenesis and tumor growth. TRC105 is a monoclonal antibody that binds CD105 to inhibit angiogenesis (IND expected in 2007). TRC102 is a small molecule that reverses resistance to chemotherapeutics that is currently being evaluated in a Phase 1 trial and TRC101 is a nanoliposome embedded with ceramide used to improve the activity and delivery of chemotherapeutics. TRACON Pharmaceuticals was founded by Paramount BioSciences, LLC.
Please visit www.traconpharma.com for more information about TRACON Pharmaceuticals, Inc.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as ``anticipates,'' ``expects,'' ``plans,'' ``believes,'' ``intends,'' and similar words or phrases. Such statements involve risks and uncertainties that could cause TRACON Pharmaceutical’s actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, and drug development and commercialization. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and TRACON Pharmaceuticals undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
###
Contact:
Alison Fishman, (858) 550-0780 ext. 229, afishman@traconpharma.com